MeSH term
Frequency | Condition_Probility | Humans | 22 | 0.0 |
*Translocation, Genetic | 4 | 0.0 |
*Chromosomes, Human, Pair 5 | 3 | 1.0 |
Receptor, Platelet-Derived Growth Factor beta/*genetics | 5 | 71.0 |
Research Support, Non-U.S. Gov't | 14 | 0.0 |
Adult | 4 | 0.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Male | 9 | 0.0 |
Middle Aged | 5 | 0.0 |
Piperazines/*therapeutic use | 5 | 10.0 |
Pyrimidines/*therapeutic use | 5 | 11.0 |
Receptor, Platelet-Derived Growth Factor beta/metabolism | 2 | 16.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 3 | 1.0 |
*Repressor Proteins | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Chromosomes, Human, Pair 5 | 3 | 2.0 |
Myeloproliferative Disorders/*drug therapy/*genetics | 2 | 100.0 |
Piperazines/*pharmacology | 2 | 3.0 |
Pyrimidines/*pharmacology | 2 | 3.0 |
Translocation, Genetic | 3 | 0.0 |
Base Sequence | 2 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Infant | 2 | 0.0 |
Animals | 5 | 0.0 |
Child | 2 | 0.0 |
Chromosomes, Human, Pair 22/*genetics | 2 | 2.0 |
Female | 4 | 0.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Blotting, Southern | 3 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Comparative Study | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Mice | 4 | 0.0 |
DNA | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Aged | 2 | 0.0 |
